Patterson: 32:30 thank you Nader it's 32:38

New Post Public Reply Private Reply Replies (4) Message Board
trding trding #8116
711
Patterson:
32:30 thank you Nader it's
32:38 certainly a pleasure to be here talking
32:40 about one of my favorite subjects I
32:43 think it was a face that I met Nader
32:46 because I've spent 22 years working on
32:48 ccr5 first 15 in HIV funded by the
32:54 National Institutes of Health the last
32:56 five in the immuno oncology space
32:58 through my company incellDX the
33:02 important point about
33:03 ccr5 you see a lot of different in the
33:05 patience here you might say how can it
33:07 be effective against all of these
33:09 different indications well the fact is
33:12 ccr5 inhibitor Pro 140 it's like the
33:16 quarterback of the immune system so if
33:19 you look at any of those indications
all
33:21 of them are driven by immune
33:23 responsiveness or a lack of immune
33:26 responsiveness and ccr5 is critical in
33:29 both of those contexts in terms of our
33:33 deal that we signed we indeed have
33:35 already ordered from CytoDyn our first
33:39 lot of pro 140 label with a fluorescent
33:43 dye so that we can sting tissues and
33:46 cells and say which cancer cells and the
33:49 immune cells associated with it and
33:51 which cells that HIV infects are
33:54 actually occupied by Pro 140 we actually
33:58 have the ideal tool to go to the FDA and
34:00 say listen this drug is working and an
34:03 irrespective of the viral load we know
34:06 this drug is working some of the things
34:08 that we're seeing on the ongoing HIV
34:11 trials are fascinating because Pro 140
34:15 acts on the cells that HIV infects and
34:18 protects them from being infected the
34:22 hallmark of HIV is the destruction of
34:24 the immune system as we all know and
34:26 AIDS right if you preserve the immune
34:30 system you're fine you have a competent
34:34 immune system that's what pro 140 does
34:36 it doesn't go in and inhibit the virus
34:40 like some of these other drugs do which
34:43 happen to be a lot more toxic than ccr5
34:46 but it blocks additional cells from
34:49 being infected which is really the
34:51 hallmark that's the goal of what
34:53 everybody should be looking for a good
34:55 analogy is I relate to you trying to
34:57 start a fire on your grill and you have
35:00 no charcoal but you have lighter fluid
35:02 so sometimes the lighter fluid will
35:05 light which I relate to an increase in
35:07 viral load but there's nothing to
35:10 propagate the fire so that you can cook
35:13 your hamburgers
35:13 right leronlimab
35:16 blocks the key cells that propagate
35:19 infection you need to prolonged
35:21 increases of viral load that's the
35:24 message that has to go to the FDA that
35:26 this drug is completely occupying the
35:29 receptors that it needs to occupy and
35:31 it's blocking virus from binding to
35:33 uninfected cells and preserving the
35:36 immune system that's where we all want
35:39 to be
and in cancer ccr5 has been around
35:43 for a long time and it's not about ccr5
35:46 on the tumor
35:47 it's about ccr5 on certain immune cells
35:51 that that control the tumor okay so
35:54 there's two eight billion dollar-a-year
35:56 drugs called opdivo and keytruda
36:00 made by Merck and BMS that bring back
36:03 your own immune system to fight off the
36:05 tumor but you know what happens after
36:08 three to six months they stopped working
36:10 why do they stop working well this whole
36:13 new wave of cells comes in to shut that
36:17 immune response off that's part of the
36:19 elegance of our body in controlling you
36:23 know a immune response gone awry right
36:26 but in cancer we want the immune
36:28 response to go awry right those immune
36:32 cells called T reg cells that come in
36:34 and supposedly shut off the light switch
36:37 that opdivo and keytruda have turned back
36:40 on Express ccr5 so if we get pro 140 it
36:45 can block those cells from coming in and
36:48 shutting off the immune response that
36:50 you just spent two hundred thousand
36:52 dollars a year to bring back in the
36:54 patient it's a tremendous opportunity
36:56 this is a immuno oncology drug it is it
37:01 always has been and you know it hasn't
37:04 come to the forefront until just
37:06 recently
now that we have more
37:08 information on how this immune response
37:11 against tumors is is regulated the other
37:14 thing that pro 140 does is it
37:16 reprogrammed
37:17 a cell called a macrophage think of
37:20 pac-man that little guy that goes around
37:22 and gobbles up little things on the
37:24 computer game
37:25 well macrophages come and gobble up
37:28 tumor cells normally right but when
37:31 they're when they're blocked by CCL 5
37:34 which is a protein made by t-cells they
37:38 don't go and gobble up the tumor cells
37:39 when you block with pro 140 those
37:43 macrophages are now active against the
37:45 tumor again so this is extremely
37:49 exciting immuno Oncology drug and you
37:53 know what I think the field is just
37:54 starting to realize it it's the
37:56 quarterback of cells moving in the body
37:59 to where they need to be and prolong for
38:02 taking control of that and now we have a
38:05 diagnostic that says this drug is going
38:07 to bind exactly
in the past we've been
38:11 looking at ccr5 expression with antibody
38:13 bodies made by Dickinson and
38:15 other companies the problem is that
38:18 doesn't bind to the exact site that Pro
38:20 140 does so what we did in our deal is
38:23 we made sure that when we're doing
38:25 Diagnostics to see if there's a
38:27 candidate for pro 140 we're going to use
38:30 the actual drug as a diagnostic it's
38:34 elegant it's extremely elegant and it's
38:37 going to be much more specific and
38:39 accurate in defining the patients that
38:41 are going to respond and at the end of
38:43 the day we're all going to benefit from
38:45 that so I can't tell you how excited I
38:48 am about this and when you look at these
38:50 boards and all the different indications
38:51 it's easy to say well we're all over
38:53 the place in reality we're not what
38:56 we're just doing is taking advantage of
38:58 all the different disease states that
39:00 ccr5 is active in and this drug has
39:04 applications for all of those yet we
39:07 need to focus on the ones that are at
39:09 hand and get the HIV applications
39:12 approved but after that the pipeline
39:15 after that they'll just keep feeding
39:17 keep feeding the utility of pro 140 is
39:21 extremely excited really really exciting
39:25 both for the emulation standpoint and a
39:28 viral logic standpoint and again
39:30 for my work at Northwestern first and
39:33 then at Stanford this is what I spent my
39:35 life doing and finally this is coming to
39:38 the forefront so and I'm happy to answer
39:40 any questions any time show you any data
39:44 that we have internally that may not be
39:46 out to the masses or out to the FDA yet
39:48 because it is really really exciting
39:51 when I'm looking at this data coming off
39:53 our machines every single day there's
39:56 not a single day where I can't wait to
39:58 get into work and see that
so we
40:09 definitely answer any question

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 23

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 14

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading